EMPA-REG OUTCOME (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients) was the first major trial published evaluating SGLT2-i use for reduction of MACE in patients with type 2 diabetes and known CVD on empagliflozin
( 10.1126/sciadv.aaz9890) [DOI] [PMC free article] [PubMed] [Google Scholar] 95.Kliewer SA, Mangelsdorf DJ
not recommended for use with DPP-4 inhibitors Common side effects : Gastrointestinal symptoms (nausea, vomiting, diarrhea) that typically diminish with continued use and proper dose titration Referral to endocrinology or obesity medicine specialists is appropriate for complex cases, including patients with multiple failed therapies, significant comorbidities, or those requiring comprehensive weight management programs
Basically, in ASAP, the broad adoption of early cooked or ripened foods, Flour added food materials, is fueling a rise in diabetes cases, which ultimately accelerates demand for GLP-1 receptor agonists
Compounding can also be done by an outsourcing facility
Adding protein, fiber and healthy fats made all the difference. Carlos: I felt awful and realized I was dehydrated
